Beating cancer, one test at a time.

Oncimmune profiles the body’s immune response to detect evidence of the body’s natural response to cancer, which can be detected far earlier than cancerous cells themselves, or the cancer’s DNA.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT—Lung and EarlyCDT—Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT—Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland.

Oncimmune is headquartered in Nottingham (UK) with a CLIA lab in Kansas (US) and offices in London (UK), Dortmund (Germany) and Shanghai (China).

Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016.

Oncimmune acquired the immuno-profiling company PROTAGEN AG in March 2019.

Our proprietary platform — underpinned by rapid biomarker discovery and our comprehensive immunogenic protein library of over 8,000 antigenic proteins — has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making; and is a keystone to the future of cancer care.

Our patented technology measures blood levels of autoantibodies to tumour-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.

Oncimmune is working to change how cancer is diagnosed and treated. Whilst early detection is already improving cancer survival, immuno-profiling is the frontier to improving outcomes.

Key Fundamentals 31-May-15 31-May-16 31-May-17 31-May-18
Revenue (£ m) 1.34 0.43 0.22 0.24
Pre-Tax (£ m) -2.01 -9.01 -5.32 -6.34

Major Shareholders
As at 30th April 2019, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:

No of Ordinary Shares %
• BALDERTON CAPITAL III, LP1 10.8
• GENOSTICS COMPANY LTD2 10.1
• Richard Sharp 7.1
• RUFFER LLP 5.3
• Geoffrey Hamilton-Fairley 5.1
• FIL INVESTMENT INTERNATIONAL 4.9
• Timothy Bunting 4.4
• MILTON ASSET MANAGEMENT 4.0
• UNIVERSITY OF NOTTINGHAM 3.5